PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Global Psoriatic Arthritis Treatment Market Size and Trends

Global psoriatic arthritis treatment market size is estimated at USD 13.41 Bn in 2026 and is expected to reach USD 26.13 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 10.0% from 2026 to 2033.

Key Takeaways of the Global Psoriatic Arthritis Treatment Market

• In terms of drug class, the biologics segment is estimated to contribute the highest market share of 51.5% in 2026.
• In terms of product type, the prescription segment is estimated to contribute the highest market share of 55.5% in 2026.
• In terms of route of administration, the parenteral segment is estimated to contribute the highest market share of 64.5% in 2026.
• North America has established itself as the dominant player in the global psoriatic arthritis treatment market with an estimated market share of 40. 7% in 2026.

Market Overview

Global psoriatic arthritis treatment market growth is driven by rising prevalence of psoriatic arthritis across the world. Technological advancements in diagnosis and treatment of psoriatic arthritis have led to the development of newer drug classes such as interleukin inhibitors, which have improved clinical outcomes and quality of life of patients. However, high costs associated with biologic drugs for psoriatic arthritis treatment and patent expiries of blockbuster drugs can hamper the market growth.

Market Driver - Rising prevalence of psoriatic arthritis

According to the latest available estimates, nearly 30 million people worldwide suffer from psoriasis. Out of which, approximately 30% of patients suffer from psoriatic arthritis (PsA). Most physicians earlier assumed PsA to be a minor issue or a precursor to psoriasis but now clearly recognize it as a chronic inflammatory disease requiring long term treatment approach.

Population based studies show that nearly 50% of patients experience PsA onset before psoriasis, indicating delayed diagnosis is often the case. Even in developed markets, many patients have undiagnosed PsA for years, which has caused permanent joint damage by the time it was detected. Growing health impacts of PsA in terms of physical disability, impaired body functions, and mental health issues compel patients to seek treatment options.

Market Concentration and Competitive Landscape

Current Events and their Impact

Impact of AI on Global Psoriatic Arthritis Treatment Market

• AI is transforming psoriatic arthritis (PsA) treatment by accelerating diagnoses and personalizing therapies, exemplified by initiatives like iPROPLEPSIS that use machine learning with wearable devices and mobile health apps.
• Predictive modeling, such as Tel Aviv University's PredictAI, significantly reduces diagnostic delays for PsA by identifying key markers from electronic health records, achieving 89% accuracy in flagging high-risk patients 18-24 months in advance.
• AI-powered patient management solutions, like ArtiMetrix's virtual assistant, optimize treatment by predicting biologic DMARD effectiveness with 82% accuracy, leading to higher remission rates and reduced medication costs.

Market Trends

Diverse Therapies & Strong Pipeline

The psoriatic arthritis treatment market is gaining serious momentum, largely due to a rise in diagnoses and the steady introduction of targeted therapies. There's a noticeable uptick in innovation, especially with selective TYK2 inhibitors and next-gen IL-17 inhibitors making their way through clinical trials. These newer drugs are designed to offer more tailored treatment, particularly for patients who haven’t responded well to existing options.

A good example is Bristol Myers Squibb’s Sotyktu, a TYK2 inhibitor that showed strong results in a Phase 3 trial. It not only met its endpoints but outperformed existing treatments, which makes it a promising new oral option for PsA patients looking for something more effective.

Biosimilar Surge & Affordability Focus

A major game-changer is the rise of biosimilars. As patents expire on existing biologic drugs, many lower-cost biosimilar versions are entering the market. This creates fierce competition, pushing down prices, and making advanced therapies more accessible. The focus is shifting towards providing effective, yet affordable, and treatment options.

Market Opportunity - Development of Biosimilars

Global psoriatic arthritis treatment market can offer growth opportunities due to the development of biosimilar drugs. Biosimilars are essentially cheaper generic versions of original patented biologics whose patents have expired. With patents of some major blockbuster biologics like Humira, Remicade, and Enbrel expiring in the next few years, numerous pharma companies are in the race to develop high quality biosimilars for these drugs.

Increased adoption of such lower-cost biosimilars can enhance affordability and accessibility of biologic treatment regimens for psoriatic arthritis patients globally. It will also offer pharma companies an attractive revenue opportunity in the market. 

Segment Analysis

Global Psoriatic Arthritis Treatment Market Insights by Drug Class

In terms of drug class, the biologics segment is estimated to contribute the highest market share of 51.5% in 2025, owing to their targeted approach. Biologics such as tumor necrosis factor (TNF) inhibitors directly target specific components of the immune system associated with psoriatic arthritis, offering more effective relief of symptoms compared to traditional non-biologics.

 As the pathophysiology of psoriatic arthritis becomes better understood, biologics that block cytokines like TNF, interleukin-17 (IL-17), and interleukin-23 (IL-23) have revolutionized treatment. Patients and physicians alike recognize that biologics provide superior clinical efficacy in relieving pain, swelling, and stiffness with many able to achieve disease remission. 

Global Psoriatic Arthritis Treatment Market Insights by Product Type

In terms of product type, the prescription segment is estimated to contribute the highest market share of 55.5% in 2026. Unlike over-the-counter (OTC) alternatives, prescription medications for psoriatic arthritis directly target underlying disease mechanisms, offering patients more effective symptom relief.

Prescriptions can be tailored to an individual's condition severity and medical history to optimize therapy based on a provider's expertise. Prescription fill data further enables healthcare professionals to monitor patients, identify any lapses in compliance, and adjust treatment plans accordingly. Convenient characteristics like syncing prescription refills with other medications support compliance.

Global Psoriatic Arthritis Treatment Market Insights by Route of Administration

In terms of route of administration, the parenteral segment is estimated to contribute the highest market share of 64.5% in 2026, owing to benefits over oral delivery. Biologic drugs that suppress inflammation through targeted cytokine inhibition have revolutionized treatment but require injection or infusion administration.

Injection sites can be rotated to minimize discomfort or irritation at any one location over time. Reimbursement programs and specialty pharmacy services also help manage costs and support needs for parenteral biologics over the long-term. These collective advantages of the parenteral administration route drive its market share dominance for treating psoriatic arthritis, especially as biologics become standard first-line therapies.

Regional Insights

North America Psoriatic Arthritis Treatment Market

North America has established itself as the dominant player in the global psoriatic arthritis treatment market with an estimated market share of 40.7% in 2025. With a well-developed healthcare infrastructure and high per capita healthcare expenditure, the U.S. accounts for the majority of the regional market share.

Asia Pacific Psoriatic Arthritis Treatment Industry Trends

Asia Pacific represents the fastest growing regional market due to rapidly developing healthcare infrastructure across major countries like China and India. Growing medical tourism coupled with increased accessibility of treatment options drives the regional market growth.

Presence of several contract manufacturers engaged in active pharmaceutical ingredients and drug formulation has further strengthened the Asia Pacific industry landscape. However, lack of stringent regulatory guidelines and intellectual property protection pose challenges to market growth.

Europe Psoriatic Arthritis Treatment Market

European market, though well-established, still presents significant opportunities for market players. Presence of universal healthcare coverage combined with supportive government policies ensure affordable access and widespread adoption of advanced therapies. Stringent regulations are pertaining to clinical trials and product approvals delay market entry of new therapies. Regional players may also face intense competition from global pharma majors headquartered outside of Europe.

U.S. Psoriatic Arthritis Treatment Industry Analysis

The U.S. psoriatic arthritis treatment industry is rapidly evolving, driven by the increasing use of highly effective biologics like TNF, IL-17, and IL-12/23 inhibitors and the growing impact of more affordable biosimilars. This is fostering competition and expanding access. There's also a strong pipeline of novel targeted therapies such as JAK and TYK2 inhibitors, pointing towards more personalized treatment approaches and continued market growth.

Incidence and Epidemiology

• The global prevalence of Psoriatic Arthritis (PsA) varies significantly, from 0.06% to 1.0%, largely influenced by geographic and genetic factors, with higher rates observed in North America and Europe.
• According to a comprehensive meta-analysis published in April 2024, psoriatic arthritis (PsA) affects 112 out of every 100,000 adults globally, with higher rates observed in Europe and North America than in Asia and Latin America.
• While PsA is not directly fatal, it substantially increases the risk of mortality due to associated conditions like cardiovascular disease, leading to a reduced life expectancy. 

Market Report Scope

Global Psoriatic Arthritis Treatment Industry News

• On May 22, 2025, Bio-Thera Solutions and Hikma Pharmaceuticals announced U.S. FDA approval for Starjemza (ustekinumab-hmny), an eighth biosimilar to Stelara
• In May 2025, Biocon Biologics announced that its commercial partner in Japan, Yoshindo Inc., launched Ustekinumab BS Subcutaneous Injection [YD], a biosimilar to Stelara (ustekinumab). Biocon Biologics had already launched Ustekinumab in the U.S. and Europe in February 2025.
• In March 2025, Bristol Myers Squibb presented detailed data from its POETYK PsA-2 trial at the American Academy of Dermatology (AAD) Annual Meeting in Orlando, U.S. The presentation demonstrated the superiority of Sotyktu (deucravacitinib), an oral selective TYK2 inhibitor, compared with placebo in adults with psoriatic arthritis.
• In March 2024, Acelyrin, Inc. announced promising results from its global phase 2b/3 clinical trial of izokibep, a small protein therapeutic targeting IL-17A, showing potential as a breakthrough treatment for psoriatic arthritis. Izokibep demonstrated exceptional potency, strong tissue penetration, and a prolonged half-life. The robust product pipeline and the expansion of treatment applications are expected to drive market growth.
• In October 2023, Novartis announced that the FDA had approved an intravenous (IV) formulation of Cosentyx (secukinumab) for treating adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). This IV option, targeting interleukin-17A (IL-17A), is the only non-TNF-α IV treatment for these conditions.

Analyst View

• The psoriatic arthritis treatment market stands at a critical inflection point where traditional approaches are being systematically dismantled by precision medicine advances
• The treatment accessibility gap between developed and emerging markets isn't just a pricing issue but a strategic miscalculation. While pharmaceutical companies chase premium pricing in saturated Western markets, the real volume opportunities lie in Asia Pacific regions where early intervention could prevent long-term disability costs.
• JAK inhibitors were positioned as the next revolution, yet their safety profile limitations have exposed the industry's tendency to oversell therapeutic potential. The FDA's black box warnings for JAK inhibitors reveal how regulatory bodies are becoming increasingly skeptical of incomplete safety data presented during accelerated approval processes. This regulatory tightening signals a fundamental shift that will eliminate the fast-track mentalities that have defined recent market dynamics.

Market Segmentation

•  Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
• Biologics
• Non-biologics
• Combination Therapy
•  Product Type Insights (Revenue, USD Bn, 2021 - 2033)
• Prescription
• Over-The-Counter (OTC)
•  Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
• Parenteral
• Oral
•  Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Medtronic
• Johnson & Johnson (DePuy Synthes)
• Zimmer Biomet
• Stryker
• Xtant Medical
• RTI Surgical
• SeaSpine
• Arthrex
• HansBioMed
• Exactech
• Wright Medical Group
• Bioventus
• Integra LifeSciences
• AlloSource
• Medline Industries
• Osiris Therapeutics
• Acelity
• Orthofix
• MTF Biologics
• Cerapedics

Sources

Stakeholders:

• Pharmaceutical Industry Executives
• Rheumatologists and Dermatologists
• Healthcare Policy Analysts
• Patient Advocacy Group Representatives
• Others

Magazines:

• Pharmaceutical Technology Magazine
• Rheumatology Advisor
• The American Journal of Managed Care
• Others

Journals:

• The Journal of Rheumatology
• Arthritis & Rheumatology
• Clinical and Experimental Rheumatology
• Others

Newspapers:

• The Wall Street Journal (Healthcare Section)
• Financial Times (Pharmaceutical Insights)
• Reuters Health News
• Others

Associations:

• National Psoriasis Foundation (NPF)
• American College of Rheumatology (ACR)
• Global Healthy Living Foundation
• Others

Public Domain Sources:

• National Institutes of Health (NIH) Publications
• World Health Organization (WHO) Reports
• Centers for Disease Control and Prevention (CDC) Data
• Others

Proprietary Elements:

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of Information for Last 8 Years

*Definition: Global Psoriatic Arthritis Treatment Market involves pharmaceutical and biopharmaceutical companies developing, manufacturing, and marketing drug therapies to treat psoriatic arthritis. It covers oral and injectable medications for reducing joint swelling and pain, slowing disease progression, and improving physical function in patients suffering from this chronic inflammatory arthritis condition. Major products in this market include tumor necrosis factor inhibitors, interleukin inhibitors, conventional systemic therapies, and biosimilars.